R. Dent, M. Trudeau, K. I. Pritchard, W. M. Hanna, H. K. Kahn et al., Triple-negative breast cancer: clinical features and patterns of recurrence, Clin Cancer Res, vol.13, pp.4429-4434, 2007.

C. Liedtke, C. Mazouni, K. R. Hess, F. André, A. Tordai et al., Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer, J Clin Oncol, vol.26, pp.1275-1281, 2008.

S. Loi, N. Sirtaine, F. Piette, R. Salgado, G. Viale et al., Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98, J Clin Oncol, vol.31, pp.860-867, 2013.

S. Loi, S. Michiels, R. Salgado, N. Sirtaine, V. Jose et al., Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial, Ann Oncol, vol.25, pp.1544-1550, 2014.

S. Adams, R. J. Gray, S. Demaria, L. Goldstein, E. A. Perez et al., Prognostic value of tumorinfiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199, J Clin Oncol, vol.32, pp.2959-2966, 2014.

C. Denkert, S. Loibl, A. Noske, M. Roller, B. M. Müller et al., Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer, J Clin Oncol, vol.28, pp.105-113, 2010.

Y. Issa-nummer, D. , S. Loibl, S. Kunz, G. Nekljudova et al., Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer-a substudy of the neoadjuvant GeparQuinto trial, PLoS One, vol.8, 2013.

B. D. Lehmann, J. A. Bauer, X. Chen, M. E. Sanders, A. B. Chakravarthy et al., Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies, J Clin Invest, vol.121, pp.2750-2767, 2011.

H. Masuda, K. A. Baggerly, Y. Wang, Y. Zhang, A. M. Gonzalez-angulo et al., Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes, Clin Cancer Res, vol.19, pp.5533-5540, 2013.

B. D. Lehmann, B. Jovanovic, X. Chen, M. V. Estrada, K. N. Johnson et al., Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection, PLoS One, vol.11, 2016.

S. Dawood, S. D. Merajver, P. Viens, P. B. Vermeulen, S. M. Swain et al., International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment

, Ann Oncol, vol.22, pp.515-523, 2011.

T. M. Fouad, T. Kogawa, J. M. Reuben, and N. T. Ueno, The role of inflammation in inflammatory breast cancer, Adv Exp Med Biol, vol.816, pp.53-73, 2014.

H. Masuda, K. A. Baggerly, Y. Wang, T. Iwamoto, T. Brewer et al., Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers, Breast Cancer Res, vol.15, 2013.

S. J. Van-laere, N. T. Ueno, P. Finetti, P. Vermeulen, A. Lucci et al., Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct affymetrix gene expression datasets, Clin Cancer Res, vol.19, pp.4685-4696, 2013.

,

S. Dawood, N. T. Ueno, V. Valero, W. A. Woodward, T. A. Buchholz et al., Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study, Cancer, vol.117, pp.1819-1826, 2011.

X. Chen, J. Li, W. H. Gray, B. D. Lehmann, J. A. Bauer et al., TNBCtype: a subtyping tool for triple-negative breast cancer, Cancer Inform, vol.11, pp.147-156, 2012.

B. Z. Ring, D. R. Hout, S. W. Morris, K. Lawrence, B. L. Schweitzer et al., Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients, BMC Cancer, vol.16, p.26908167, 2016.

A. Poggi and M. G. , Mesenchymal stromal cells can regulate the immune response in the tumor microenvironment, Vaccines, vol.4, p.41, 2016.

A. Dongre, M. Rashidian, F. Reinhardt, A. Bagnato, Z. Keckesova et al., Epithelial-to-mesenchymal transition contributes to immunosuppression in breast carcinomas, Cancer Res, vol.77, pp.3982-3989, 2017.

B. T. Hennessy, A. M. Gonzalez-angulo, K. Stemke-hale, M. Z. Gilcrease, S. Krishnamurthy et al., Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics, Cancer Res, vol.69, pp.4116-4124, 2009.

M. Miyashita, H. Sasano, K. Tamaki, M. Chan, H. Hirakawa et al., Tumor-infiltrating CD8+ and FOXP3+ lymphocytes in triple-negative breast cancer: its correlation with pathological complete response to neoadjuvant chemotherapy, Breast Cancer Res Treat, vol.148, p.25395319, 2014.

C. Ginestier, C. Iovino, F. Tarpin, C. Diebel, M. Esterni et al., Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer, Clin Cancer Res, vol.16, pp.45-55, 2010.
URL : https://hal.archives-ouvertes.fr/hal-01431949

S. A. Ibrahim, R. Gadalla, E. A. El-ghonaimy, O. Samir, H. T. Mohamed et al., Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways, Mol Cancer, vol.16, p.28270211, 2017.